Vitrectomy combined with posterior-segment Ahmed valve implant: A case series study

Frutos-Lezaun, M. de; Rodríguez-Agirretxe, Iñaki; Labairu, F. Eder; Irigoyen, Cristina

doi:10.1016/j.sjopt.2018.03.002

Cited by 3 publications

(6 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We could not infer whether the BCDVA improvements in these eyes were due to postoperative IOP control or removal of the cataract. However, similar to de Frutos-Lezaun et al 's study [17], in our cohort, the overall BCDVA did not differ significantly from the preoperative value to the latest follow-up value. In contrast, Wallsh et al [18] and Jeong et al [21] reported postoperative improvements in BCVA.…”

Section: Faghihi Et Al (2007) [24]supporting

confidence: 90%

“…To the best of our knowledge, this is the first study on AGV implantation for refractory glaucoma in the Caribbean region. Furthermore, the present study had the largest sample size with the longest follow-up among other studies on this topic [16][17][18][19][20][21][22][23][24][25].…”

Section: Introductionmentioning

confidence: 82%

“…Future studies should explore success rate for various subtypes of glaucoma and surgical approaches for AGV tube implantation. The success rate in similar studies on AGV implantation in the PP and PPV varied from 71.4% to 100%, with follow-up periods ranging from 12 to 28 months and various ocular comorbidities but the same IOP preset for successful control, which was < 21 mmHg [ 16 , 17 , 20 , 21 , 23 - 25 , 31 ]. Our success rate ranged from 50.62% to 100% across follow-ups and reached 88.89% at the latest follow-up; the mean IOP was always < 18 mmHg.…”

Section: Discussionmentioning

confidence: 99%

“…Two eyes developed phthisis bulbi. Owing to the diversity in ocular comorbidity and ocular status among the included eyes in studies on PPAV [17,18,20,21,23,24,25,31], the exact cause of some complications is difficult to determine, and relating these complications to the method of AGV implantation seems to be irrational.…”

Section: Faghihi Et Al (2007) [24]mentioning

confidence: 99%

“…Patients with refractory glaucoma who had underlying retinal pathology showed satisfactory outcomes when treated with PPV with combined [12,13] or consecutive [14,15] Ahmed glaucoma valve (AGV) implantation in the anterior chamber (AC). Evidence is limited for combined [16][17][18] or consecutive [19] AGV implantation with PPV, mainly because it is more commonly placed in AC, although a few studies have been reported [16][17][18][19][20][21]. Complex refractory glaucoma is treated at our center using vitrectomy combined with AGV placed in the posterior segment rather than the common AC.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Long-term outcome of pars plana Ahmed valve implant and vitrectomy in eyes with refractory glaucoma

Dubay¹,

Dwarika²,

Bhola³

et al. 2022

Med Hypothesis Discov Innov Ophthalmol

View full text Add to dashboard Cite

Background: Pars plana vitrectomy with implantation of an Ahmed glaucoma valve in the vitreous cavity has been reported with a success rate in the management of refractory and neovascular glaucoma. This study aimed to present the outcomes of pars plana Ahmed glaucoma valve (PPAV) surgical implantation in cases with refractory glaucoma. Methods: In this single-center, retrospective, comparative study, 87 consecutive patients diagnosed with refractory glaucoma who underwent PPAV surgical implantation between October 2015 and October 2019 were evaluated. A successful post-op outcome was defined as postoperative intraocular pressure (IOP) less than or equal to 21 mmHg upon examination and a reduction in the number of anti-glaucoma agents used at the latest follow-up. Results: As a final count, 81 eyes of 78 patients with refractory glaucoma were included; 54 (66.66%) of the eyes had neovascular glaucoma. The mean follow-up was 20.65 ± 12.17 months (range: 2?52 months). The mean pre-op IOP was 40.01 ± 1.19 mmHg and reduced significantly to 16.73 ± 0.82 mmHg at the latest follow-up (P < 0.001); thus, a successful IOP outcome was achieved in 88.89% of eyes. The mean number of anti-glaucoma agents decreased significantly from 2.86 ± 0.09 pre-operatively to 1.46 ± 0.11 at the latest follow-up (P < 0.001); while 61 (75.31%) of eyes had a reduction in the number of IOP lowering eye drops, and 14 (17.28%) had no need for IOP lowering eye drops. Conclusions: PPAV surgery is a successful procedure for IOP reduction in patients with refractory glaucoma. Our study demonstrated either elimination or reduction of IOP, lowering eye drops postoperatively. Large scale studies with a comparison group, a longer follow-up, and having various subtypes of glaucoma are required as future research to confirm these outcomes.

show abstract

Section: Faghihi Et Al (2007) [24]supporting

confidence: 90%